DaVita Inc.

DVA · NYSE · USD

Historical Earnings

Quarter	Reported	EPS est	EPS act	Surprise	Rev est	Rev act	Surprise	Reaction
Q2 2026	Aug 4, 2026	3.88	4.02	+3.6%	$3.5B	$3.6B	+1.7%	−17.24%
Q1 2026	May 5, 2026	2.41	2.87	+19.1%	$3.4B	$3.4B	+1.8%	+23.46%
Q4 2025	Feb 2, 2026	3.24	3.40	+4.9%	$3.5B	$3.6B	+3.2%	+21.17%
Q3 2025	Oct 29, 2025	3.17	2.51	−20.8%	$3.4B	$3.4B	−0.2%	−6.17%
Q2 2025	Aug 5, 2025	2.70	2.95	+9.3%	$3.4B	$3.4B	−1.8%	−9.04%
Q1 2025	May 12, 2025	1.95	2.00	+2.6%	$3.2B	$3.2B	+0.5%	−0.31%
Q4 2024	Feb 13, 2025	2.14	2.24	+4.7%	$3.3B	$3.3B	+0.9%	−11.09%
Q3 2024	Oct 29, 2024	2.72	2.59	−4.8%	$3.3B	$3.3B	−0.1%	−10.80%

Detailed View

Q3 2026Oct 29, 2026Q2 2026Aug 4, 2026−17.24%Q1 2026May 5, 2026+23.46%Q4 2025Feb 2, 2026+21.17%Q3 2025Oct 29, 2025−6.17%Q2 2025Aug 5, 2025−9.04%Q1 2025May 12, 2025−0.31%Q4 2024Feb 13, 2025−11.09%Q3 2024Oct 29, 2024−10.80%Q2 2024Aug 6, 2024Q1 2024May 2, 2024Q4 2023Feb 13, 2024

2026 Q2 Metrics

Metric	Estimate	Actual	Surprise	Y/Y
Revenue	$3.5B	$3.6B	Beat +1.65%	+5.2%
EPS	3.88	4.02	Beat +3.61%	+36.3%
Diluted EPS (GAAP)	—	4.02	—	+55.8%

Documents

Earnings call transcript — Q2 2026
Transcript · Aug 4, 2026 · 53 speaker turns
10-Q — Q2 2026
10-Q · Aug 4, 2026 · sec.gov
8-K — Q2 2026
8-K · Aug 4, 2026 · sec.gov

Analyst consensus

Hold23 analysts

Bearish · 1 · Hold · 12 · Bullish · 10

Earnings history

	EPS	Estimate
Q3 2024	$2.59	$2.72	Miss
Q4 2024	$2.24	$2.14	Beat
Q1 2025	$2.00	$1.95	Beat
Q2 2025	$2.95	$2.70	Beat
Q3 2025	$2.51	$3.17	Miss
Q4 2025	$3.40	$3.24	Beat
Q1 2026	$2.87	$2.41	Beat
Q2 2026	$4.02	$3.88	Beat

Peers

Company overview

IPO dateOct 31, 1995

CEOJavier J. Rodriguez

Employees78,000

SectorHealthcare

IndustryMedical - Care Facilities

CountryUS

ExchangeNew York Stock Exchange

Websitewww.davita.com

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.